RSS   Newsletter   Contact   Advertise with us

Conatus Pharma appoints Mason M. Yamashita as vice president

Staff writer | San Diego, Ca., USA | June 23, 2015
Conatus PharmaJune 23, 2015, San Diego, Ca., USA - Conatus Pharmaceuticals, a biotechnology company, announced the appointment of Mason M. Yamashita as vice president of pharmacovigilance.
Dr. Yamashita has been Executive Director and Vice President of Clinical Development/Drug Safety since 2011 at Isis Pharmaceuticals. He was previously Senior Director of Clinical Development from 2010 to 2011 at Ambit Biosciences, and Medical Director of Drug Safety Clinical Research from 2008 to 2010.

Dr. Yamashita was an Associate Director of Drug Safety Clinical Research from 2007 to 2008 at Biogen Idec, Associate Medical Director of Clinical Development from 2006 to 2007 and Manager/Senior Manager of Preclinical Development from 2003 to 2006 at Neurocrine Biosciences, and Associate Director of Preclinical Development from 2001 to 2003 at CancerVax. He previously worked as a scientist at Signal Pharmaceuticals and Vertex Pharmaceuticals.

Dr. Yamashita received an M.D. from the John A. Burns School of Medicine at the University of Hawaii, a Ph.D. in Physical Chemistry from the University of California, Los Angeles, and a B.S. in Chemistry from the University of Hawaii.

Dr. Yamashita completed an internship in 2001 at the University of California, San Diego, with a focus on psychiatry and neurology, and a fellowship in 1998 at The Scripps Research Institute with a focus on the development of cellular assays to test novel anti-tumor compounds.


 LATEST MOVES FROM California 


MORE INSIDE POST